- Home
- / Pyxis Oncology
Pyxis Oncology
Stock Price
$3.8
2024-10-29
Market Capitalization
$227 M
2024-10-29
Revenue
$13.9 M
FY, 2025
Pyxis Oncology Summary
Company Summary
- Overview
- Pyxis Oncology is a preclinical oncology company focused on developing therapeutics to target difficult-to-treat cancers. Its product candidates include antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies such as PYX-201, PYX-202, and PYX-203.
- Type
- Public
- Status
- Active
- Founded
- 2019
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Pamela Connealy, Chief Financial Officer
Jay M. Feingold, Chief Medical Officer
Darren Cline, Director
LocationsView all
1 location detected
Cambridge, MA HQ
United States
35 Cambridge Park Dr
Pyxis Oncology Financials
Summary Financials
- Net income (Q1, 2026)
- ($23.3M)
- Cash (Q1, 2026)
- $5.8M
- EBIT (Q1, 2026)
- ($24.4M)
- Enterprise value
- $239.5M